Black checkmark with a sparkle and a curved line underneath on a white background.
Company

ASTROTECH Corp

Ticker
ASTC
Sector
Industry
Report date
November 13, 2026
Valye AI Score

98

Very high visibility
Recent developments
Recent developments summary

Recent developments include financial results showing increased full-year losses, leadership changes, product development milestones, and new product launches across subsidiaries.

Recent developments:
  • Astrotech reported an increased full-year loss as of September 2026, reflecting operational challenges and cost pressures [N1].
  • The company announced updates to indemnification and leadership arrangements in February 2026 [N2].
  • Q2 2026 results showed a reduction in net loss compared to prior periods [N3].
  • In May 2025, Astrotech appointed Jennifer Cañas as Chief Financial Officer [N5].
  • The company reported Q3 fiscal year 2025 financial results and product development milestones in May 2025 [N6].
  • Astrotech launched an enhanced TRACER 1000 narcotics trace detector to address the synthetic drug crisis in March 2025 [N7].
  • EN-SCAN, Inc. was launched in February 2025 to develop innovative environmental testing solutions [N8].
Overview

Astrotech Corporation develops and commercializes advanced analytical technologies based on its proprietary Astrotech Mass Spectrometer Technology (AMS Technology) platform. The company operates through five wholly-owned subsidiaries, each licensed exclusively to apply the AMS Technology in distinct markets: 1st Detect focuses on explosives and narcotics trace detection for security applications; AgLAB targets the hemp and cannabis agriculture market with mass spectrometry solutions to optimize distillation yields; BreathTech develops breath analysis tools for medical screening; Pro-Control provides industrial process control instrumentation for chemical distillation; and EN-SCAN offers rugged environmental testing instruments for real-time air, water, and soil analysis. Astrotech also pursues early-stage Lunar Initiatives aimed at developing infrastructure technologies for semiconductor processing and advanced computing on the lunar surface. The company reported $274 thousand in revenue and a net loss of $2.95 million for the quarter ended September 30, 2026, with cash and equivalents of $5.6 million and a current ratio of 7.24, reflecting strong liquidity despite recurring operational losses. Recent developments include product certifications, government contract awards, leadership appointments, and new product launches across its subsidiaries.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Astrotech Corporation is a technology company commercializing mass spectrometry and gas chromatography platforms through wholly-owned subsidiaries targeting security, agriculture, breath analysis, industrial process control, and environmental testing markets. The company reported $274 thousand revenue and a net loss of $2.95 million for the quarter ended September 30, 2026, with strong liquidity ratios and ongoing investments in product development and strategic lunar initiatives. Recent news highlights include leadership changes, product launches, and financial results reflecting operational challenges and cost management efforts.

Scenarios for ASTC

Bull case model:

Astrotech's proprietary AMS Technology platform underpins a diversified portfolio of subsidiaries addressing high-demand markets including security screening, agriculture, industrial process control, and environmental monitoring. The TRACER 1000's certifications and deployments across multiple countries demonstrate commercial traction in explosives and narcotics detection. AgLAB's field trials indicate potential for significant yield improvements in the growing hemp and cannabis market. EN-SCAN's rugged environmental testing instruments address regulatory compliance needs with real-time data capabilities. The company's strong liquidity ratios provide operational runway to support ongoing product development and commercialization efforts. Strategic initiatives in lunar infrastructure and advanced computing represent potential long-term growth avenues, leveraging unique environmental advantages of the Moon.

Bear case model:

Astrotech faces recurring net losses and negative cash flows from operations, with an accumulated deficit exceeding $268 million as of September 30, 2026. Revenue remains modest and fluctuates with contract and product sales. The company's Lunar Initiatives are in early exploratory stages without commercial operations or finalized plans, carrying substantial technical, financial, and execution risks. Market adoption of AMS Technology-based products depends on regulatory approvals, customer acceptance, and competitive dynamics, including entrenched ion mobility spectrometry technologies. Operational expenses remain significant, with recent increases in selling, general and administrative costs. The company relies on external financing sources to meet liquidity needs, which may be uncertain. Product development and commercialization efforts may face delays or challenges impacting financial performance.

Moat:

Astrotech's competitive advantage derives from its proprietary Astrotech Mass Spectrometer Technology platform, which offers smaller, less expensive, and easier-to-use mass spectrometry devices operating under ultra-high vacuum to reduce false alarms and improve detection resolution. The company holds 17 patents and extensive trade secrets protecting its intellectual property. Exclusive licensing of the AMS Technology to its subsidiaries enables focused application development across diverse markets such as security, agriculture, industrial process control, and environmental testing. Certifications by regulatory bodies like the European Civil Aviation Conference and approvals by the U.S. Transportation Security Administration for its TRACER 1000 product enhance market credibility. The company's ability to expand detection libraries without degrading performance differentiates its explosives trace detectors from ion mobility spectrometry-based competitors. Additionally, government contracts and inclusion on the U.S. General Services Administration IT Schedule 70 facilitate access to federal customers. However, the company's early-stage Lunar Initiatives face significant technical and commercial uncertainties.

Risks overview
Risks summary
Astrotech's biggest risks include the technical and commercial uncertainties of its early-stage Lunar Initiatives, ongoing operational losses requiring external financing, and challenges in market adoption of its AMS Technology products amid competition and regulatory hurdles.
Risks details:

• Early-stage Lunar Initiatives: The Lunar Initiatives are exploratory with no commercial operations, requiring substantial investments and technical expertise. They face risks related to technical feasibility, financing, customer demand, partnerships, and regulatory approvals.
• Recurring Losses and Cash Flow Deficits: Astrotech has a history of net losses and negative operating cash flows, with an accumulated deficit of approximately $268.2 million, necessitating ongoing access to external capital to fund operations.
• Market Adoption and Competition: The company's AMS Technology products compete against established ion mobility spectrometry-based detectors and other analytical instruments. Market acceptance depends on regulatory certifications, performance, and customer preferences.
• Operational Expense Management: Selling, general and administrative expenses have increased due to consulting and interim leadership costs, while research and development expenses have fluctuated with headcount changes and reclassifications.
• Regulatory and Commercialization Challenges: Certain products, such as BreathTech's breath analysis tool, face lengthy regulatory approval processes and require significant investment, impacting commercialization timelines and capital allocation.

FINAL FORECAST FOR ASTC

Final take one line
Astrotech Corporation operates a diversified mass spectrometry technology platform with multiple subsidiaries addressing security, agriculture, industrial, and environmental markets, supported by strong intellectual property and liquidity but facing operational losses and early-stage lunar initiatives risks.
Final take 12 to 24 month view

Business trends: Continued commercialization of AMS Technology through subsidiaries with product launches and government certifications; exploration of lunar infrastructure initiatives.
Execution milestones: Progress in product development and deployment of TRACER 1000 detectors; leadership appointments; financial management to sustain operations.
Key risks: Technical and commercial uncertainties of lunar initiatives; recurring operational losses requiring external financing; regulatory and market adoption challenges for AMS Technology products.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

98
LLM visibility overview
LLM Visibility known facts
  • Astrotech Corporation (Nasdaq: ASTC) is a Delaware corporation organized in 1984 focused on commercializing mass spectrometry and gas chromatography technologies.
  • The company owns the Astrotech Mass Spectrometer Technology (AMS Technology) platform, which is licensed exclusively to five wholly-owned subsidiaries for different applications.
  • Subsidiaries include 1st Detect (explosives and narcotics trace detectors), AgLAB (mass spectrometers for hemp and cannabis agriculture), BreathTech (breath analysis tools), Pro-Control (industrial process control mass spectrometers), and EN-SCAN (environmental testing and monitoring solutions).
  • 1st Detect's TRACER 1000 is the world's first MS-based explosives trace detector certified by the European Civil Aviation Conference and approved by the TSA for air cargo security, deployed in approximately 37 locations across 16 countries as of June 30, 2026.
  • AgLAB's 1000-D2 mass spectrometer series targets the hemp and cannabis market to optimize distillation yields, with field trials showing yield improvements of 20% or more.
  • BreathTech developed the BreathTest-1000 for screening volatile organic compounds in breath but has paused commercialization due to regulatory and investment challenges.
  • Pro-Control provides mass spectrometry solutions for industrial chemical distillation process control outside agriculture, aiming to improve reaction intermediates, purity, and yields.
  • EN-SCAN offers rugged, portable gas chromatography-based instruments for real-time environmental testing of air, water, and soil contamination, with plans to incorporate mass spectrometry in future products.
  • Astrotech has initiated Lunar Initiatives focused on developing infrastructure technologies for semiconductor processing, advanced computing, and quantum manufacturing on the lunar surface; these initiatives are in early exploratory stages without commercial operations or finalized plans.
  • Financial snapshot as of September 30, 2026: cash and equivalents $5.6 million, current assets $13.4 million, current liabilities $1.85 million, current ratio 7.24, cash ratio 4.94.
  • For the three months ended September 30, 2026, revenue was $274 thousand, gross margin 37%, net loss $2.95 million, reflecting decreased contract revenue and increased material costs.
  • Operating expenses decreased 16% year-over-year for the quarter, with selling, general and administrative expenses increasing due to consulting and interim CFO costs, and research and development expenses decreasing due to headcount reductions and reclassifications.
  • Cash used in operating activities was $3.2 million for the quarter, with net cash decrease of $2.8 million, partially offset by financing proceeds from equity programs.
  • The company has recurring losses and negative cash flows from operations with an accumulated deficit of approximately $268.2 million as of September 30, 2026.
  • Recent news highlights include full year loss increases reported in September 2026, Q2 loss reduction in February 2026, leadership changes including appointment of a new CFO in May 2025, product development milestones, and new product launches such as the enhanced TRACER 1000 narcotics detector and EN-SCAN environmental testing solutions.
  • The TRACER 1000 ETD and NTD are listed on the U.S. General Services Administration IT Schedule 70, enabling sales to the U.S. federal government.
  • The AMS Technology is designed to be smaller, less expensive, and easier to use than traditional mass spectrometers, operating under ultra-high vacuum to reduce false alarms and improve resolution.
  • The company faces risks related to the early-stage Lunar Initiatives, including technical, financial, and commercial viability uncertainties, and the need for significant ongoing investments and expertise.
  • The company monitors financing and capital sources to meet liquidity requirements given recurring losses and negative cash flows.
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-09-25 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-09-25 | www.nasdaq.com | Astrotech Corp. Full Year Loss Increases | https://www.nasdaq.com/articles/astrotech-corp-full-year-loss-increases
  • N2 | 2026-02-14 | www.nasdaq.com | Astrotech Updates Indemnification and Leadership Arrangements | https://www.nasdaq.com/articles/astrotech-updates-indemnification-and-leadership-arrangements
  • N3 | 2026-02-13 | www.nasdaq.com | Astrotech Corp. Q2 Loss Drops | https://www.nasdaq.com/articles/astrotech-corp-q2-loss-drops
  • N4 | 2025-09-26 | www.nasdaq.com | Astrotech Corp. Full Year Loss Rises | https://www.nasdaq.com/articles/astrotech-corp-full-year-loss-rises
  • N5 | 2025-05-28 | www.nasdaq.com | Astrotech Corporation Appoints Jennifer Cañas as Chief Financial Officer | https://www.nasdaq.com/articles/astrotech-corporation-appoints-jennifer-canas-chief-financial-officer
  • N6 | 2025-05-13 | www.nasdaq.com | Astrotech Corporation Reports Q3 Fiscal Year 2025 Financial Results and Product Development Milestones | https://www.nasdaq.com/articles/astrotech-corporation-reports-q3-fiscal-year-2025-financial-results-and-product
  • N7 | 2025-03-10 | www.nasdaq.com | Astrotech Corporation Launches Enhanced TRACER 1000™ Narcotics Trace Detector to Combat Synthetic Drug Crisis | https://www.nasdaq.com/articles/astrotech-corporation-launches-enhanced-tracer-1000tm-narcotics-trace-detector-combat
  • N8 | 2025-02-28 | www.nasdaq.com | Astrotech Corporation Launches EN-SCAN, Inc. to Develop Innovative Environmental Testing Solutions | https://www.nasdaq.com/articles/astrotech-corporation-launches-en-scan-inc-develop-innovative-environmental-testing
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine